Lynne Garrity-Ryan

Paratek Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index1.4kcitations28works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotic Resistance in Bacteria(12), Antimicrobial Resistance in Staphylococcus(10), Antibiotics Pharmacokinetics and Efficacy(9), Antibiotic Use and Resistance(7), Pneumonia and Respiratory Infections(6)

Publications28 total

Sub-growth-inhibitory concentrations of omadacycline inhibit <i>Staphylococcus aureus</i> haemolytic activity <i>in vitro</i>
JAC-Antimicrobial Resistance·2021· 1 citedOpen Access
Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia
International Journal of Infectious Diseases·2021· 18 citedOpen Access
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment
International Journal of Antimicrobial Agents·2020· 9 citedOpen Access
1202. Subinhibitory Concentrations of Omadacycline Inhibit <i>Staphylococcus aureus</i> Hemolytic Activity in Vitro
Open Forum Infectious Diseases·2020· 1 citedOpen Access
110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
Open Forum Infectious Diseases·2019· 2 citedOpen Access
734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
Open Forum Infectious Diseases·2019· 2 citedOpen Access
700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
Open Forum Infectious Diseases·2019· 1 citedOpen Access
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial
The Lancet Infectious Diseases·2019· 92 cited
Omadacycline for Bacterial Infections
New England Journal of Medicine·2019· 1 cited
Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
Antimicrobial Agents and Chemotherapy·2019· 36 citedOpen Access
Omadacycline for Community-Acquired Bacterial Pneumonia
New England Journal of Medicine·2019· 215 citedOpen Access
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
New England Journal of Medicine·2019· 148 cited
Impact of age and gender on efficacy and safety of omadacycline (OMC) vs. moxifloxacin (MOX) in community-acquired bacterial pneumonia (CABP)
2018
Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
Antimicrobial Agents and Chemotherapy·2017· 37 citedOpen Access
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
Antimicrobial Agents and Chemotherapy·2017· 46 citedOpen Access
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
Antimicrobial Agents and Chemotherapy·2017· 134 citedOpen Access
Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies
Open Forum Infectious Diseases·2017· 5 citedOpen Access
A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)
Open Forum Infectious Diseases·2017· 11 citedOpen Access
<i>In Vitro</i> and <i>In Vivo</i> Antimalarial Efficacies of Optimized Tetracyclines
Antimicrobial Agents and Chemotherapy·2013· 12 citedOpen Access
Small Molecule Inhibitors of LcrF, a <i>Yersinia pseudotuberculosis</i> Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model
Infection and Immunity·2010· 71 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Amy Manley(13), Evan Tzanis(13), Paul C. McGovern(9), Surya Chitra(8), Judith N. Steenbergen(7), Sébastien Tanaka(7), Anita Das(6), Paul B. Eckburg(6), Evan Loh(6), Stephen Villano(5), Courtney Kirsch(4), Joanne N. Engel(4), Stuart B. Levy(4), Michael N. Alekshun(4), Stephen A. Bai(4), Marla Curran(4), Oak K. Kim(3), Victoria J. Bartlett(3), Roman Stets(2), Monica Popescu(2)